Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
5.12
+0.31 (6.44%)
At close: Mar 10, 2026, 4:00 PM EDT
5.25
+0.13 (2.54%)
After-hours: Mar 10, 2026, 7:45 PM EDT

Myriad Genetics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
149.6102.4132.156.9257.4
Short-Term Investments
--8.85881.4
Cash & Short-Term Investments
149.6102.4140.9114.9338.8
Cash Growth
46.09%-27.32%22.63%-66.09%124.82%
Accounts Receivable
115.3121.2114.3101.691.3
Inventory
30.627.52220.115.3
Other Current Assets
37.146.936.43839.4
Total Current Assets
332.6298313.6274.6484.8
Net Property, Plant & Equipment
163.4172.4180.6187.3125.3
Other Intangible Assets
153.4262.4349.5379.7404.1
Goodwill
51.6286.3287.4286.8239.2
Long-Term Investments
---54.859
Other Long-Term Assets
5.68.515.415.58.3
Total Assets
706.61,0281,1471,1991,321
Accounts Payable
3032.325.828.829.6
Accrued Expenses
96.9119113.994.3161.7
Current Portion of Leases
6.912.816.214.113
Total Current Liabilities
133.8164.1155.9137.2204.3
Long-Term Debt
119.939.638.5--
Long-Term Leases
8387.997.4130.979.3
Other Long-Term Liabilities
1.934.971.544.869.3
Total Long-Term Liabilities
204.8162.4207.4175.7148.6
Total Liabilities
338.6326.5363.3312.9352.9
Common Stock
0.90.90.90.80.8
Additional Paid-in Capital
1,4891,4581,4161,2601,226
Accumulated Other Comprehensive Income
0.8-0.8-3.7-8.9-5.1
Retained Earnings
-1,123-756.8-629.5-366.2-254.2
Shareholders' Equity
368701.1783.2885.8967.8
Total Liabilities & Equity
706.61,0281,1471,1991,321
Total Debt
209.8140.3152.114592.3
Net Cash (Debt)
-60.2-37.9-11.2-30.1246.5
Net Cash Per Share
-0.65-0.42-0.14-0.373.16
Book Value
368701.1783.2885.8967.8
Book Value Per Share
3.977.749.4610.9912.41
Tangible Book Value
163152.4146.3219.3324.5
Tangible Book Value Per Share
1.761.681.772.724.16
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q